Latest Content

Discuss depression care challenges, comorbidities, and new treatments—submit cases, research, or CME ideas for Psychiatric Times’ September 2026 series.

Review the developments in GLP-1s in 2026.

A target trial emulation of more than 1.5 million matched adults ties GLP-1 RA initiation to lower mortality and cardiovascular events in serious mental illness.

New trial shows edible THC worsens lane control and reaction time at low blood levels, raising doubts about current legal impairment limits.

ACP outlines ethical AI use in medicine—protect patient trust, curb bias, prevent deskilling, and guide transparent, equitable care.

Yale trio-genomics study links hair-pulling and skin-picking to inherited OCD risk scores and rare DNA variants, hinting at shared brain pathways.

International Overdose Awareness Day marks 25 years, spotlighting fragile declines in deaths and urging naloxone access, harm reduction funding, and stigma-free care.

Much of what we call "treatment-resistant" depression may be mismatched, not resistant. A psychiatrist makes the case for trading the failed-drug tally for a difficult-to-treat framework clinicians can act on Monday morning.

BioVie completes treatment visits in a phase 2 long COVID trial of bezisterim targeting brain fog and fatigue, with topline results expected September 2026.

Axsome launches SUMMIT phase 3 testing AXS-05 to help adults quit smoking, comparing it with bupropion and placebo over 12 weeks.

Neurobiology of antisocial behavior links prenatal stress, childhood trauma, toxins, and brain-circuit deficits to proactive vs reactive aggression and psychopathy.

Review news in psychiatry from the last week.

Livestreamed insanity trials reshape public opinion, exposing myths, bias, and psychiatry’s educator role, in cases like the M’Naghten trial to the curent Clancy trial.